Navigation Links
FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
Date:11/17/2009

LAKE ZURICH, Ill., Nov. 17 /PRNewswire/ -- Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has cleared the Verax Platelet PGD® test as a quality control test to detect bacterial contamination in whole blood-derived, pooled platelets prior to transfusion. Fenwal is the exclusive global distributor of the test, which was developed by Verax Biomedical of Worcester, Mass.

The Verax Platelet PGD® test is the only rapid diagnostic test to receive FDA clearance for detecting bacteria in both pooled and single-donor platelets. The test can be performed in approximately 30 minutes and is designed for use in hospitals, cancer centers and other sites of care as a safeguard prior to transfusion.

Bacterial contamination in platelets is a serious threat to transfusion safety. More than 5 million platelet doses are transfused annually worldwide. Studies show that up to 1 in 2,000 doses may contain bacteria, which can cause a range of reactions, including death, especially in immune-compromised patients.

The international blood transfusion association AABB (www.aabb.org) issued an Association Bulletin in July 2009 stating that "after publication of data sufficiently robust to support application of an assay appropriate for use near the time of platelet issue, the current standard will be reappraised. At that time, AABB intends to promulgate an interim standard to require enhanced methods of bacterial detection in WBD platelets--either by specifically prohibiting the use of less sensitive methods such as pH or glucose, or by establishing a minimum sensitivity level for methods used to detect bacteria." The Verax Platelet PGD® test is an example of such an assay.

"Until now, there was no rapid test cleared by t
'/>"/>

SOURCE Fenwal, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
2. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
3. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
4. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
5. FDA Clears a Test for Ovarian Cancer
6. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
7. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... GLENWOOD, Ill. , Aug. 22, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... announced today that William E. Saxelby , its ... as President and Chief Executive Officer and as a ... September 15, 2014.  He will be replaced on an ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... A placebo controlled study involving top ice ... reaction times reduced by one fifth in players using the ... were given 12 minutes of bright light via the ear ... by the Department of Exercise and Medical Physiology at Verve ...
...   SA Health , the public health system of South ... it signed the final agreement to deploy the Sunrise ... solutions from Allscripts (NASDAQ: MDRX ) ... hospitals and health clinics serve a population of 1.6 million ...
Cached Medicine Technology:Bright Light Therapy via Ear Canals Improved Reaction Times of Top Athletes in a Placebo-Controlled Psycho-Motoric Study 2Australia's SA Health Finalizes Allscripts Agreement 2Australia's SA Health Finalizes Allscripts Agreement 3Australia's SA Health Finalizes Allscripts Agreement 4
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... Pakulski that uses university-proven research to show people how they ... of lean muscle in only a matter of weeks has ... , “Ben Pakulski is one of the most well-known ... to get the body he has today, that in itself ...
(Date:8/22/2014)... the first time an oncogenic somatic mutation at amino ... has been identified in small cell lung cancer (SCLC) ... cell lines produced increased intracellular signaling and cell growth. ... cancer representing 15% of all lung cancers and is ... lung cancer, has been extensively examined for genomic alterations ...
(Date:8/22/2014)... (RA), a complex autoimmune disease that affects 1 ... not only cope with pain, disability and joint ... work, family life and marital functioning. While many ... and disability is common. In addition, some patients ... or side effects. Because of this, there is ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... Dr. Sen and Dr. Samantha Pearson to help people ... and avoid corrective vision surgery by instead improving their ... prompting an investigative review. , “There’s a reason ... dollars in revenue each year—it’s because people just assume ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4
... for Prevention, Mental,Health and Low-Income Programs, Boosted ... Today a minority of,the U.S. Senate ... for the 44 million Americans who depend ... Providers Act, which would have improved,Medicare,s prevention, ...
... Would Have Improved Benefits for Prevention, Mental,Health and ... FE, N.M., June 12 SUMMARY: Today a,minority ... protect and,improve Medicare for the 44 million Americans ... and Providers Act, which would have,improved Medicare,s prevention, ...
... Corporation,(Nasdaq: PODD ), the leader in patch ... announced the Company will participate in,the William Blair ... scheduled to present an overview of the Company ... The Four Seasons Hotel in Chicago, IL., ...
... 12 Benchmark findings from the,study, conducted ... (BEB),suggest that formal management of training program ... one of the key success drivers in,effective ... Download a complimentary excerpt of this member-driven ...
... Senate voted 54,to 39 in favor of S. ... of 2008. However, that did not achieve the ... provisions that provide,prompt payment of Medicare Part D ... reimbursement cuts for generic prescription,drugs. In response Bruce ...
... complaints of insomnia predicted a healthier life, study finds ... is associated with healthy aging, a new study found. ... assessed 2,226 women aged 60 and older for use ... awakening, snoring, overall sleep quality, and sleep duration. Based ...
Cached Medicine News:Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Better Sleepers Are 'Successful Agers' 2
... of DOA Panel Test is ... in vitro test. It is ... substances in human urine specimens. ... in the point of care ...
... a qualitative immunoassay intended to ... usage of cocaine by detecting ... in human urine at a ... It is for health care,professional ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... delivers performance, value and safety ... smaller laboratories. It's an affordable, ... small sample volume in both ... a wide operating range and ...
Medicine Products: